LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

Search

Twist Bioscience Corp

Fechado

SetorSaúde

31.46 4.48

Visão Geral

Variação de preço das ações

24h

Atual

Mín

29.01

Máximo

31.66

Indicadores-chave

By Trading Economics

Rendimento

60M

20M

Vendas

3.3M

96M

Margem de lucro

21.227

Funcionários

923

EBITDA

22M

-24M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+39.06% upside

Dividendos

By Dow Jones

Próximos Ganhos

14 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

96M

1.9B

Abertura anterior

26.98

Fecho anterior

31.46

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Twist Bioscience Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de nov. de 2025, 23:51 UTC

Ganhos

CoreCivic Cuts Fiscal Year Guidance Amid Efforts to Launch New Detention Facilities

5 de nov. de 2025, 23:10 UTC

Ganhos

DBS Third Quarter Net Dips 2.0%

5 de nov. de 2025, 22:55 UTC

Ganhos

Arm Holdings 2Q Profit Climbs on Record Demand

5 de nov. de 2025, 22:23 UTC

Ganhos

NAB's Annual Profit Falls 2.9% Amid Higher Costs, Credit Impairments -- Update

5 de nov. de 2025, 23:52 UTC

Ganhos

United Overseas Bank 3Q Net Interest Income S$2.265B Vs. $2.46B >U11.SG

5 de nov. de 2025, 23:49 UTC

Ganhos

United Overseas Bank 3Q Total Income S$3.40B Vs. S$3.83B >U11.SG

5 de nov. de 2025, 23:49 UTC

Ganhos

United Overseas Bank 3Q Net S$443M Vs. Net S$1.61B >U11.SG

5 de nov. de 2025, 23:45 UTC

Conversa de Mercado

Nikkei May Rise on Weaker Yen, U.S. Tech Rebound -- Market Talk

5 de nov. de 2025, 23:42 UTC

Conversa de Mercado

Gold Edges Lower Amid Reduced Odds of Fed Rate-Cut -- Market Talk

5 de nov. de 2025, 23:12 UTC

Ganhos

Nutrien 3Q Adj EPS 97c >NTR.T

5 de nov. de 2025, 23:11 UTC

Ganhos

Nutrien: Initiating Review of Strategic Alternatives for Phosphate Business >NTR.T

5 de nov. de 2025, 23:10 UTC

Ganhos

Nutrien 3Q Sales $6.01B >NTR.T

5 de nov. de 2025, 23:10 UTC

Conversa de Mercado
Ganhos

AppLovin Says Conversion Rate Is Biggest Growth Lever -- Market Talk

5 de nov. de 2025, 23:10 UTC

Ganhos

Nutrien 3Q EPS 96c >NTR.T

5 de nov. de 2025, 23:04 UTC

Ganhos

Qualcomm Stock Slides After Earnings Beat -- Barrons.com

5 de nov. de 2025, 23:03 UTC

Conversa de Mercado

Macklem: Canada's Regulatory Overlap Turns Off Foreign Investors -- Market Talk

5 de nov. de 2025, 22:55 UTC

Conversa de Mercado

Macklem Says Inflation and Productivity Are Intertwined -- Market Talk

5 de nov. de 2025, 22:55 UTC

Ganhos

AppLovin Reports Strong Earnings. The Stock Is Up. -- Barrons.com

5 de nov. de 2025, 22:51 UTC

Ganhos

DBS 3Q Total Income S$5.93B, Up 3% on Year >D05.SG

5 de nov. de 2025, 22:50 UTC

Ganhos

DBS 3Q Net S$2.95B, Down 2.0% on Year >D05.SG

5 de nov. de 2025, 22:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Pfizer Preps Improved Offer in Metsera Bidding War -- Update

5 de nov. de 2025, 22:43 UTC

Conversa de Mercado
Ganhos

NAB's Flat Dividend Disappoints Bears at Jarden -- Market Talk

5 de nov. de 2025, 22:36 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

5 de nov. de 2025, 22:36 UTC

Conversa de Mercado

Macklem Warns Structural Adjustment Means Slow Canadian Growth -- Market Talk

5 de nov. de 2025, 22:20 UTC

Conversa de Mercado

Bank of Canada Says Budget Plan Identifies Economy's Biggest Weakness -- Market Talk

5 de nov. de 2025, 22:12 UTC

Aquisições, Fusões, Aquisições de Empresas

Pfizer: Will Take Action to Preserve Rights Under Previously-Signed Agreement >PFE

5 de nov. de 2025, 22:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Pfizer: Confident in Merits of Claims, Belief Metsera Has Acted in Breach of Contractual Obligations >PFE

5 de nov. de 2025, 22:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Pfizer Responds to Delaware Chancery Court Ruling

5 de nov. de 2025, 22:01 UTC

Ganhos

Great-West Lifeco 3Q Net C$1.16B >GWO.T

5 de nov. de 2025, 22:01 UTC

Ganhos

Great-West Lifeco 3Q Adj EPS C$1.33 >GWO.T

Comparação entre Pares

Variação de preço

Twist Bioscience Corp Previsão

Preço-alvo

By TipRanks

39.06% parte superior

Previsão para 12 meses

Média 41.8 USD  39.06%

Máximo 50 USD

Mínimo 36 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Twist Bioscience Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

5 ratings

5

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

31.56 / 38.6884Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat